financetom
Business
financetom
/
Business
/
Xylem Q1 Adjusted Earnings, Revenue Rise; 2024 Outlook Lifted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Xylem Q1 Adjusted Earnings, Revenue Rise; 2024 Outlook Lifted
May 2, 2024 5:09 AM

07:37 AM EDT, 05/02/2024 (MT Newswires) -- Xylem (XYL) reported Q1 adjusted earnings Thursday of $0.90 per diluted share, up from $0.79 a year earlier.

Analysts polled by Capital IQ expected $0.84.

Revenue for the quarter ended March 31 was $2.03 billion, up from $1.45 billion a year earlier.

Analysts surveyed by Capital IQ expected $2 billion.

For 2024, the water technology company now expects adjusted earnings of $4.10 to $4.25 per share on revenue of $8.5 billion, compared with its Feb. 6 guidance of $4 to $4.20 per share on revenue of $8.4 billion to $8.5 billion. Analysts surveyed by Capital IQ expect adjusted earnings of $4.14 per share on revenue of $8.5 billion.

Xylem shares were up 1% in recent premarket trading.

Price: 131.00, Change: +0.04, Percent Change: +0.03

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved